The impact of Bruton’s tyrosine kinase inhibitor treatment on COVID-19 outcomes in Chinese patients with chronic lymphocytic leukemia

MLA

Shenmiao Yang, et al. “The Impact of Bruton’s Tyrosine Kinase Inhibitor Treatment on COVID-19 Outcomes in Chinese Patients with Chronic Lymphocytic Leukemia.” Frontiers in Oncology, vol. 14, May 2024. EBSCOhost, https://doi.org/10.3389/fonc.2024.1396913.

APA

Shenmiao Yang, Rong Wei, Hongxia Shi, Yazhe Wang, Yueyun Lai, Xiaosu Zhao, Jin Lu, & Norbert Schmitz. (2024). The impact of Bruton’s tyrosine kinase inhibitor treatment on COVID-19 outcomes in Chinese patients with chronic lymphocytic leukemia. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1396913

Chicago

Shenmiao Yang, Rong Wei, Hongxia Shi, Yazhe Wang, Yueyun Lai, Xiaosu Zhao, Jin Lu, and Norbert Schmitz. 2024. “The Impact of Bruton’s Tyrosine Kinase Inhibitor Treatment on COVID-19 Outcomes in Chinese Patients with Chronic Lymphocytic Leukemia.” Frontiers in Oncology 14 (May). doi:10.3389/fonc.2024.1396913.